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Objectives 13 
To assess the performance of the Gram negative-specific antibiotic temocillin  in 14 
polymethylmethacrylate (PMMA) bone cement  pre-loaded with gentamicin, as a strategy for local 15 
antibiotic delivery.  16 
Methods 17 
Temocillin was added at varying concentrations to commercial gentamicin-loaded bone cement. The 18 
elution of the antibiotic from cement samples over a two week period was quantified by HPLC-MS. 19 
The eluted temocillin was purified by fast protein liquid  chromatography and minimum inhibitory 20 
concentration (MIC) for a number of antibiotic-resistant Escherichia coli determined. The impact 21 
strength of antibiotic-loaded samples was determined using a Charpy-type impact testing apparatus. 22 
Results 23 
HPLC-MS data showed temocillin eluted to clinically significant concentrations within 1 h in this 24 
laboratory system and the eluted temocillin retained antimicrobial activity against all organisms 25 
tested. Impact strength analysis showed no significant difference between cement samples with or 26 
without temocillin. 27 
Conclusions 28 
Temocillin can be added to bone cement and retains its antimicrobial activity after elution. The 29 
addition of up to 10% temocillin did not affect the impact strength of the cement. The results show 30 
that temocillin is a promising candidate for use in antibiotic loaded bone cement. 31 
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 33 
Introduction 34 
In the UK during 2012, bone cement was used in 54% of total primary hip replacements (including 35 
21% hybrid cemented/cementless procedures) and 86% of total primary knee replacements (including 36 
<1% hybrid procedures), equating to approximately 150,000 arthroplastic operations. The use of 37 
antibiotic-loaded cement in primary hip replacement procedures has increased from 73% in 2004 to 38 
89% in 2012. Similarly the use of antibiotic-loaded cement in primary knee replacement procedures 39 
has increased from 87% in 2003 to 98% in 2012.1 Adding one or more prophylactic antibiotics to 40 
cement has been shown to reduce postoperative infection rates.2 Due to the wide range of organisms 41 
that can contribute to prosthetic joint infections and problems with antibiotic-resistant bacteria, an 42 
increasing range of antibiotics need to be available for addition to bone cement.   43 
Temocillin is a β-lactam antibiotic resistant to hydrolysis by most β-lactamases, due to the presence of 44 
6-α-methoxy group, which stabilizes the molecule against hydrolysis by many such enzymes.3,4  A 45 
substantial minority of prosthetic joint infections are caused by Gram negative bacteria , most notably  46 
Enterobacteriaceae such as Escherichia coli, Klebsiella spp. and Proteus spp.5-7 Temocillin is 47 
effective against organisms expressing a range of extended spectrum β-lactamases (ESBL), including 48 
some carbapenem resistant species.8-10 We envisage that if temocillin could be used as a locally 49 
delivered antimicrobial for orthopaedic surgery, the most likely context in which it would be 50 
employed would be in combination with gentamicin. Gentamicin is a well-established additive to 51 
bone cement that gives protection against Gram positives such as Staphylococci which are the most 52 
common cause of prosthetic joint infection.11,12  In such a situation, temocillin (which does not show 53 
antagonistic interaction with gentamicin4) would give protection against Gram negatives, including 54 
gentamicin resistant organisms such as ESBL-producers, possibly in revision surgery in patients with 55 
a history of infection of the prosthesis with an ESBL-producing Gram-negative organism.   56 
 57 
Methods 58 
 Temocillin was added at varying concentrations to gentamicin-containing Refobacin Bone Cement R 59 
(Biomet). Bone cement was mixed in a HiVac mixing bowl according to manufacturer's instructions 60 
and set in 5 mm × 9 mm diameter plastic moulds. Bone cement was allowed to cure for 1 h then 61 
stored at -20°C. The bone cement samples were submerged in 0.1 M ammonium acetate solution and 62 
aliquots taken at 0, 1, 2, 6, 24, 48, 72, 168 and 336 h (14 days). Eluted temocillin and gentamicin 63 
concentrations were quantified by LC-MS using a Phenomenex Luna C18 (2) column coupled to a  64 
Finnigan LCQ ion trap Mass spectrometer. The isocratic mobile phase for detection of temocillin 65 
consisted of 60 % (v/v) acetonitrile 0.1 % (v/v) trifluoroacetic acid at a flow rate of 0.05 mL/min. For 66 
detection of gentamicin an isocratic mobile phase of 40 % (v/v) methanol 0.1 % (v/v) trifluoroacetic 67 
acid at a flow rate of 0.05 mL/min was used. The use of volatile ammonium acetate solution as a 68 
buffer (rather than a standard buffer such as phosphate buffered saline) allowed direct analysis of the 69 
eluate by HPLC using electrospray ionisation MS, without the need for a desalting step. The mass 70 
spectrometer was operated with an ESI source in positive ion mode with a source voltage of 4.5 kV, 71 
sheath gas flow 80 (arbitrary units), and capillary temperature 250 °C. Detection of antibiotic was 72 
carried out using selected ion monitoring at 437 m/z corresponding to the temocillin sodium adduct 73 
[M + Na] + or 478 m/z corresponding to the protonated gentamicin C1 component [M + H] +. 74 
Antibiotic concentration was determined by linear regression to a standard calibration curve with a 75 
correlation coefficient (R
2
) of >0.99 for each antibiotic.  Method validation was carried out by 76 
analysing standard solutions  of each antibiotic (n=3) at 10 mg/L 100 mg/L and 400 mg/L over 5 77 
hours and on 3 separate days to determine interday and intraday variation respectively. Temocillin 78 
analysis showed an interday coefficient of variation (%CV) ranging from 0.98 - 5.33 and an intraday 79 
%CV ranging from 5.47 - 13.00. Gentamicin analysis showed an interday %CV ranging from 4.25 - 80 
11.61 and an intraday %CV ranging from 12.05 - 19.98. Temocillin samples eluted during the first 24 81 
hours of bone cement elution assays were pooled, separated from gentamicin by fast protein liquid 82 
chromatography using a HiTrap SP 5mL ion exchange column (GE Healthcare) and MICs for a 83 
number of Escherichia coli strains determined by broth micro-dilution method.13 The MIC values for 84 
eluted temocillin were compared to the MIC values for a standard temocillin solution determined 85 
using the same method. Impact analysis of bone cement samples was carried out using a Charpy-type 86 
Hounsfield plastic impact testing apparatus14,15 and statistical analysis was carried out using Analysis 87 
of Variance function in Microsoft Excel software.   88 
Results 89 
Kinetics of antibiotic elution 90 
When bone cement samples containing temocillin at various concentrations and gentamicin at 1.25 % 91 
(w/w) were placed in buffer solution to allow elution of the antibiotic, the highest concentration of 92 
eluted temocillin was 3051 ± 264 mg/L after 336 h (14 days) in eluate from the cement samples 93 
containing  temocillin at 10% (w/w) (Fig. 1b). Similar samples containing 5% and 1.25%  (w/w) 94 
temocillin produced lower concentrations of temocillin, at 1337 ± 427 mg/L and 327 ± 91 mg/L, 95 
respectively, after 336 h (Fig. 1b). In contrast gentamicin concentration was highest from the cement 96 
sample containing 1.25% temocillin (1380 ± 290 mg/L of gentamicin after 336 h) (Fig 1d). The 97 
samples containing 5% and 10% temocillin gave 400 ± 170 mg/L and 490 ± 180 mg/L of eluted 98 
gentamicin, respectively, after the same period of elution. 99 
 100 
Activity of the eluted temocillin 101 
MICs of the eluted temocillin were measured against several strains of E. coli (Table 1) after 102 
chromatographic separation from the eluted gentamicin, in order to confirm that the temocillin 103 
retained its antimicrobial activity after incorporation into the bone cement and subsequent elution.  104 
Results were compared against the MICs determined a standard solution of temocillin that had not 105 
been in contact with bone cement.   The MICs determined using the eluted and standard temocillin 106 
solutions were comparable for all strains tested and in line with published data for temocillin-107 
susceptible strains.16 Hence temocillin retained its antimicrobial activity after elution from the bone 108 
cement.  The range of MICs observed for the different strains can be attributed to varying (low) levels 109 
of resistance that would be expected between different isolates of these types. 110 
Impact analysis 111 
The results of the impact analysis showed no significant difference in the impact strength of bone 112 
cement containing 1.25 % (w/w) gentamicin with or without temocillin at   (P > 0.05) (see 113 
supplementary Figure S1 114 
Discussion 115 
The data presented here show that temocillin is a promising candidate for antibiotic-loaded bone 116 
cement delivery strategies. The temocillin is not degraded by the elevated temperatures during the 117 
cement curing process and retains its antimicrobial activity, which is still detectable in the eluate up to 118 
2 weeks later.  Antimicrobial activity of the eluted temocillin was confirmed with a range of E. coli 119 
strains, including a laboratory strain (DH5α) and recent clinical isolates expressing ESBLs, of the type 120 
that might require the use of temocillin in the bone cement during a joint revision operation in a 121 
patient with a history of periprosthetic infection with such an organism. The concentrations of eluted 122 
temocillin and gentamicin exceeded MIC values for susceptible strains within the first hour of elution 123 
in this laboratory system. This result may be important in a clinical setting since it indicates that the 124 
antibiotic-loaded bone cement could provide effective antimicrobial prophylaxis during the 125 
perioperative period (hip and knee replacement operations typically take 1-2 h) and it may be 126 
beneficial that active antibiotic continues to elute during the postoperative period. Increasing the 127 
percentage of temocillin within the bone cement produced larger concentrations of eluted temocillin.  128 
An increase in the amount of temocillin from 1.25% (w/w) to 5 or 10 % (w/w) also led to an 129 
unexpected decrease in gentamicin elution of approximately 3-fold  by 336 h. The antibiotic elution 130 
experiments measured cumulative elution into a single buffer which was not replaced. When higher 131 
concentrations of antibiotic were present in the buffer, this may have affected subsequent elution of 132 
antibiotic.  This could explain  the  reduced  elution of gentamicin from the bone cement containing 133 
higher concentrations of temocillin. If there was a large initial release of temocillin into the buffer as 134 
was seen at 5 and 10% temocillin concentrations, this may have inhibited the release of gentamicin 135 
into the same buffer. Although substantial, we believe that this difference in gentamicin elution is 136 
unlikely to be clinically significant because no reduction in gentamicin elution was observed during 137 
the critical perioperative period (typically 1-2 h),17 and the eluted concentration of gentamicin in this 138 
laboratory system exceed the in the MICs of susceptible organisms such as staphylococci (typically < 139 
1 mg/L) by at least 140-fold by the time of the first sample (<1 min).13,18 In addition to its favourable 140 
elution and antimicrobial properties, up to 10% (w/w) of temocillin can be added to commercial 141 
gentamicin-containing bone cement without detrimental effect on the impact strength of the cement. 142 
However a number of other groups have carried out tests looking at different mechanical properties of 143 
bone cement and shown a detrimental effect of high loading of antibiotic on these mechanical 144 
properties. These data should be taken into account before deciding on a concentration of temocillin 145 
within bone cement.  Lautenschlager et al. showed that increasing amounts of gentamicin caused a 146 
gradual, proportional decrease in the compressive and diametral tensile strength of the bone cement. It 147 
was noted that above 11.25% gentamicin (w/w), compressive strength dropped below levels 148 
recommended in ASTM guidelines.19  Studies looking at increasing amounts of daptomycin and 149 
gentamicin showed that fatigue limits decreased with increasing antibiotic concentrations and gave 150 
optimum loading concentrations of 3.4% and 4.78-6.5% respectively.20,21 The data shown here 151 
indicate that temocillin is a promising candidate for inclusion in antibiotic-loaded bone cement that 152 
may be a useful tool in combating Gram negative prosthetic joint infection. 153 
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Fig 1 A) Elution of temocillin up to 6 hours, B) elution of temocillin from 6 - 336 hours, C) elution 
of gentamicin up to 6 hours and D) elution of gentamicin from 6 - 336 hours. Bone cement 
samples initially contained 1.25% (w/w) gentamicin and varying amount of temocillin as 
indicated. Bone cement samples were immersed without buffer change and aliquots of eluate 
analysed over 336 hours.  Results are shown as the mean of 3 separate experiments ± standard 
deviation 
 226 
 227 
E. coli strain Eluted temocillinA 
MIC (mg/L) 
Standard temocillin  
MIC (mg/L) 
DH5-α 3.8 - 7.6 3.1 
AmpC expressing strain 1.9 - 3.8 3.1 - 6.3 
SHV-1 expressing strain 3.8 - 7.6 6.3 
orthopaedic isolate from infected prosthesis  15.3 6.3 
temocillin susceptible ESBL producing strain -1 15.3 12.5 
temocillin susceptible ESBL producing strain -2 15.3 6.3 - 12.5 
Table 1.  MICs for a range of E.coli strains determined by broth microdilution method using eluted temocillin 
and standard antibiotic solutions. 
A Temocillin samples eluted during the first 24 hours of bone cement elution assays were pooled and separated from 
gentamicin using ion exchange chromotography. The concentration of temocillin was quantified by HPLC and serial 
dilutions of the purified temocillin used to determine MICs.  
